Treatment of Vertigo : A Randomized, Double-Blind Trial Comparing Efficacy and Safety of Ginkgo biloba Extract EGb 761 and Betahistine

Abstract EN

A multicenter clinical trial was performed to compare the efficacy and safety of Ginkgo biloba extract EGb 761 and betahistine at recommended doses in patients with vertigo.

One hundred and sixty patients (mean age 58 years) were randomly assigned to double-blind treatment with EGb 761 (240 mg per day) or betahistine (32 mg per day) for 12 weeks.

An 11-point numeric analogue scale, the Vertigo Symptom Scale—short form, the Clinical Global Impression Scales and the Sheehan Disability Scale were used as outcome measures.

Both treatment groups were comparable at baseline and improved in all outcome measures during the course of treatment.

There was no significant intergroup difference with regard to changes in any outcome measure.

Numerically, improvements of patients receiving EGb 761 were slightly more pronounced on all scales.

Clinical global impression was rated “very much improved” or “much improved” in 79% of patients treated with EGb 761 and in 70% receiving betahistine.

With 27 adverse events in 19 patients, EGb 761 showed better tolerability than betahistine with 39 adverse events in 31 patients.

In conclusion, the two drugs were similarly effective in the treatment of vertigo, but EGb 761 was better tolerated.

This trial is registered with controlled-trials.com ISRCTN02262139.